Member access

4-Traders Homepage  >  Shares  >  Nyse  >  Actavis Inc       US9426831031

News SummaryMost relevantAll newsSector news 

Watson Says Received Favorable Ruling Over Generic Sanctura XR

04/03/2012 | 06:19pm US/Eastern

Watson Pharmaceuticals Inc. (>> Watson Pharmaceuticals, Inc.) said it received a favorable court ruling over a patent dispute with Allergan Inc. (AGN) and its business partners regarding Watson's plans for a generic version of an overactive bladder medication.

Allergan and its partners in 2009 sued Watson and its business partners, alleging infringement of patents related to Allergan's Sanctura XR drug.

Watson said Tuesday a U.S. District Court in Delaware found several Sanctura XR patents invalid, benefiting Watson and allowing it to potentially move forward with its abbreviated new drug application for generic version of the drug, which is pending with the Food and Drug Administration.

An Allergan representative wasn't immediately available for comment.

Watson has seen strong sales of its generics as health-care companies and consumers try to reduce spending on health-related products and services. Watson is trying to expand its brand-name drug business, though it recently hit a regulatory setback with a proposed new drug to prevent premature births.

The company benefited from its introduction of authorized generic versions of Johnson & Johnson's (JNJ) Concerta treatment for attention-deficit/hyperactivity disorder in May, as well as Pfizer's (PFE) Lipitor cholesterol-lowering drug in November.

Watson in February said its fourth-quarter profit surged as the introduction of generic Lipitor and other products boosted sales.

Watson's shares closed Tuesday at $66.96 and were down 6 cents after hours. Allergan's shares closed at $95.27 and were off 10 cents after hours.

-By Ben Fox Rubin, Dow Jones Newswires; 212-416-3108;

Stocks mentioned in the article : Watson Pharmaceuticals, Inc.
React to this article
Latest news on ACTAVIS INC
05/29 ACTAVIS : Court says Actavis PLC switch of patented Alzheimer's drugs violates U..
05/29 ACTAVIS : US appeals court: Alzheimer's drug swap is anti-competitive
05/28 ACTAVIS : to Speak at Bernstein's Annual Strategic Decisions Conference 2015
05/27DJFDA Clears Two Irritable Bowel Syndrome Treatments
05/27DJFDA Clears Two Treatments for Irritable Bowel Syndrome with Diarrhea
05/27 ACTAVIS : Receives FDA Approval for VIBERZI (eluxadoline) for the Treatment of I..
05/27 ACTAVIS : Infectious Disease Experts, Scientists and Clinicians Join Forces on S..
05/26 ACTAVIS : to Speak at Bernstein's Annual Strategic Decisions Conference 2015
05/22 ACTAVIS : Confirms Appeals Court Ruling Requiring Continued Distribution of NAME..
05/22 ACTAVIS : US appeals court upholds delay in Alzheimer's drug swap
Income Statement Evolution
More Financials